TMED - ETF AI Analysis
Top Page
T. Rowe Price Health Care ETF (TMED)
TMED, the T. Rowe Price Health Care ETF, has a solid overall rating driven by strong, diversified holdings in leading healthcare names like Gilead Sciences and Intuitive Surgical, which show robust financial performance, positive earnings calls, and supportive long-term business trends. Other major positions such as Eli Lilly, UnitedHealth, and Thermo Fisher also add quality but bring risks around leverage, cash flow, and valuation, while weaker spots like Insulet and Cencora face bearish technical signals and potential overvaluation. The main risk factor for the ETF is its concentrated exposure to the healthcare sector, where high leverage, rich valuations, and segment-specific challenges can increase volatility.
TMED vs. SPDR S&P 500 ETF (SPY)
- AUM
- 34.83M
- Region
- Global
- Expense Ratio
- 0.44%
- Beta
- 0.60
- Issuer
- T. Rowe Price
- Inception Date
- Jun 11, 2025
- Dividend Yield
- 0.47%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TMED Summary
TMED is the T. Rowe Price Health Care ETF, an actively managed fund that focuses on the global health care sector rather than tracking a fixed index. It invests in a wide range of medical and biotech companies, including well-known names like Eli Lilly and UnitedHealth. This ETF may appeal to investors who want exposure to the long-term growth potential of health care and to diversify beyond the broader stock market. However, because it is concentrated in health care stocks, its value can go up and down sharply with changes in the health care industry and overall market conditions.
How much will it cost me?
TMED has an annual expense ratio of 0.44%, which means you’ll pay about $4.40 per year for every $1,000 invested. This cost is higher than the average index ETF because TMED is actively managed, with professionals selecting and adjusting the health care stocks in the portfolio.
What would affect this ETF?
TMED could benefit from global growth in health care spending, aging populations, and ongoing innovation in areas like pharmaceuticals, medical devices, and biotech, especially given its focus on major companies such as Eli Lilly, UnitedHealth, and Thermo Fisher. On the downside, it may be hurt by government efforts to control drug prices, changes to health care regulations, or economic slowdowns that pressure health insurers and providers, and as a health care–focused fund it is also more exposed to sector-specific setbacks than a broadly diversified ETF.
TMED Top 10 Holdings
TMED is leaning hard into global health care leaders, with Eli Lilly, UnitedHealth, Thermo Fisher, Gilead, and Agilent doing most of the heavy lifting. These names have been generally rising or steady, giving the fund a solid backbone in Big Pharma and medical tools. On the flip side, biotech player Alnylam and medical device maker Insulet have been lagging, acting like a bit of a brake on returns, while Intuitive Surgical’s mixed performance adds some wobble. Overall, it’s a concentrated bet on innovative health care, spread across U.S.-centric but globally exposed companies.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 5.94% | $2.07M | $1.33T | 67.86% | 72Outperform |
 UNH | UnitedHealth | 5.20% | $1.81M | $365.29B | 18.05% | 72Outperform |
 ALNY | Alnylam Pharma | 3.89% | $1.35M | $22.10B | -63.30% | 60Neutral |
 PODD | Insulet | 3.80% | $1.32M | $10.38B | -52.02% | 70Outperform |
 TMO | Thermo Fisher | 3.42% | $1.19M | $257.71B | 25.31% | 72Outperform |
 GILD | Gilead Sciences | 3.09% | $1.08M | $211.64B | 44.11% | 78Outperform |
 A | Agilent | 3.08% | $1.07M | $49.30B | 21.98% | 73Outperform |
 ISRG | Intuitive Surgical | 3.00% | $1.04M | $149.75B | -18.49% | 78Outperform |
 ELAN | Elanco Animal Health | 2.74% | $954.89K | $11.52B | 2.17% | 69Neutral |
 COR | Cencora | 2.40% | $835.58K | $63.13B | -3.04% | 70Neutral |
TMED Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMED, the sentiment is Positive. The current price of 34.34 is above the 20-day moving average (MA) of 33.88, below the 50-day MA of 34.39, and above the 200-day MA of 32.10, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 52.33 is Neutral, neither overbought nor oversold. The STOCH value of 71.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMED.
TMED Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TMED | $34.34 | $35.00(1.93% Upside) | $34.83M | 0.44% | 61Neutral |
 FMED | $32.41 | $43.51(34.26% Upside) | $54.39M | 0.50% | 59Neutral |
 MEDI | $35.20 | $45.57(29.44% Upside) | $45.93M | 0.80% | 62Neutral |
 MEDX | $38.25 | $44.13(15.38% Upside) | $17.76M | 0.85% | 65Neutral |
 BMED | $36.50 | $39.32(7.74% Upside) | $14.68M | 0.55% | 65Neutral |
 HLTH | $28.67 | $37.83(31.95% Upside) | $12.63M | 0.75% | 55Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TMED | T. Rowe Price Health Care ETF | 34.34 | 6.02 | 21.27% | |
| FMED | Fidelity Disruptive Medicine ETF | 32.41 | 6.40 | 24.59% | |
| MEDI | Harbor Health Care ETF | 35.20 | 5.26 | 17.58% | |
| MEDX | Horizon Kinetics Medical ETF | 38.25 | 7.48 | 24.29% | |
| BMED | Future Health ETF | 36.50 | 8.30 | 29.45% | |
| HLTH | Tema Healthcare AI ETF | 28.67 | 3.36 | 13.28% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.